List of Excipients in Branded Drug PERINDOPRIL ERBUMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	PERINDOPRIL ERBUMINE	perindopril erbumine	0527-1919	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	PERINDOPRIL ERBUMINE	perindopril erbumine	0527-1919	FERRIC OXIDE RED
Lannett Company Inc	PERINDOPRIL ERBUMINE	perindopril erbumine	0527-1919	LACTOSE
Lannett Company Inc	PERINDOPRIL ERBUMINE	perindopril erbumine	0527-1919	MAGNESIUM STEARATE
Lannett Company Inc	PERINDOPRIL ERBUMINE	perindopril erbumine	0527-1919	SILICON DIOXIDE
Marlex Pharmaceuticals Inc	PERINDOPRIL ERBUMINE	perindopril erbumine	10135-599	CELLULOSE, MICROCRYSTALLINE
Marlex Pharmaceuticals Inc	PERINDOPRIL ERBUMINE	perindopril erbumine	10135-599	FERRIC OXIDE RED

Generic Drugs Containing PERINDOPRIL ERBUMINE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	perindopril erbumine	0054-0110	ANHYDROUS LACTOSE
West-Ward Pharmaceuticals Corp	perindopril erbumine	0054-0110	CELLULOSE, MICROCRYSTALLINE
West-Ward Pharmaceuticals Corp	perindopril erbumine	0054-0110	MAGNESIUM STEARATE
West-Ward Pharmaceuticals Corp	perindopril erbumine	0054-0110	SILICON DIOXIDE
Aurobindo Pharma Limited	perindopril erbumine	65862-286	ANHYDROUS LACTOSE
Aurobindo Pharma Limited	perindopril erbumine	65862-286	CELLULOSE, MICROCRYSTALLINE
Aurobindo Pharma Limited	perindopril erbumine	65862-286	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in PERINDOPRIL ERBUMINE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
3	CELLULOSE, MICROCRYSTALLINE
1	LACTOSE MONOHYDRATE
3	MAGNESIUM STEARATE
3	SILICON DIOXIDE

Excipient Strategy and Commercial Opportunities for Perindopril Erbumine

Last updated: February 28, 2026

What is the role of excipients in perindopril erbumine formulations?

Excipients in perindopril erbumine serve multiple functions: improve stability, optimize bioavailability, enhance patient compliance, and facilitate manufacturing. Common excipients include diluents (lactose, microcrystalline cellulose), binders, disintegrants, lubricants, and stabilizers. Their selection influences drug release profile, shelf life, and tolerability.

How do excipient choices impact the formulation process?

Choosing appropriate excipients affects manufacturing parameters such as compression properties, moisture sensitivity, and chemical compatibility. For perindopril erbumine, stability is critical due to its sensitivity to degradation. Excipients like antioxidants (ascorbic acid) or pH adjusters (sodium bicarbonate) are incorporated to mitigate stability issues.

What are the key considerations for excipient strategy in commercial development?

1. Regulatory approval: Excipients must be approved by agencies such as FDA or EMA. They should adhere to pharmacopeial standards.
2. Formulation compatibility: Excipients should not interact adversely with perindopril erbumine.
3. Patient tolerability: Excipients like lactose may cause intolerance in some populations; alternatives include hypromellose or cellulose derivatives.
4. Supply chain reliability: Consistent sourcing of high-quality excipients ensures manufacturing stability.

What commercial opportunities arise from excipient innovation?

Reformulation for Improved Stability

Developing formulations with novel stabilizers or excipient blends can extend shelf life and reduce storage constraints. This allows for simplified logistics and broader market access, especially in regions with limited cold chain infrastructure.

Enhanced Bioavailability

Excipient optimization enables controlled-release or bioavailability-enhanced formulations. These can command premium pricing and expand market share by offering superior therapeutic profiles.

Patient-Centric Formulations

Creating excipient matrices suitable for specific populations (e.g., pediatric, geriatric) opens niche markets. For example, flavoring agents or alternative disintegrants enhance palatability and compliance.

Biosimilar and Generic Opportunities

Standardized excipient strategies facilitate scale-up and regulatory approval for generic versions. Cost-effective, stable formulations can penetrate markets where brand-name drugs face generic competition.

Regulatory and Patent Strategies

Innovative excipient combinations can support patent filings, providing patent life extensions or new composition-of-matter protections, which translate into exclusivity advantages.

Market dynamics and competitive landscape

The global antihypertensive market, including drugs like perindopril erbumine, totaled USD 17.9 billion in 2021. Excipients innovations have driven development of new formulations, with companies investing heavily in stability studies and patient-centric design. The presence of multiple approved generics emphasizes the need for differentiation via excipient strategies.

Regulatory considerations

Regulatory agencies scrutinize excipient safety, manufacturing processes, and stability data. Non-standard excipients require comprehensive safety documentation. Innovations must align with ICH guidelines (Q3A/Q3B) on impurities and stability.

---

Key Takeaways

• Excipient selection for perindopril erbumine influences stability, bioavailability, and patient adherence.
• Innovations in excipient formulation can offer competitive advantages, including extended shelf life, enhanced delivery, and market differentiation.
• Regulatory compliance and supply chain reliability are critical for scalable commercial success.
• Formulation modifications demand thorough stability and safety evaluations aligned with international standards.
• Patent strategies leveraging excipient innovation can extend product lifecycle and market exclusivity.

FAQs

1. Can excipient changes impact the bioavailability of perindopril erbumine?
Yes. Excipients influence drug dissolution and absorption. Controlled-release excipients can modify bioavailability profiles.

2. Are there excipients suitable for populations with lactose intolerance?
Yes. Alternatives include microcrystalline cellulose or hypromellose, which do not contain lactose.

3. How does excipient stability affect commercial shelf life?
Incompatibilities or instability of excipients can reduce shelf life, increase storage costs, and impact regulatory approval.

4. What excipients are typically avoided in antihypertensive formulations?
Those with known allergenic potential or stability issues, such as certain dyes or non-ionic surfactants, are avoided unless thoroughly evaluated.

5. What regulatory hurdles exist for novel excipient use?
New excipients require extensive safety testing, documentation, and approval from authorities like FDA or EMA, which can delay product launch.

---

References

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients in Solid Oral Dose Human Pharmacokinetic Studies.
[2] European Medicines Agency. (2018). ICH Q3A(R2): Impurities in new drug substances.
[3] Gawande, P., et al. (2020). Formulation Strategies for Enhancing Bioavailability of Poorly Soluble Drugs. Journal of Drug Delivery Science and Technology, 55, 101447.
[4] Soppimath, K. S., et al. (2021). Patient-centric formulations: Trends and regulatory considerations. International Journal of Pharmaceutics, 603, 120694.